🚀 VC round data is live in beta, check it out!
Silence Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Silence Therapeutics and similar public comparables like Editas Medicine, Anavex Life Sciences, Antibiotice, Foghorn Therapeutics and more.
Silence Therapeutics Overview
About Silence Therapeutics
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Founded
1994
HQ
Employees
116
Website
Sectors
Financials (LTM)
EV
$198M
Silence Therapeutics Financials
Silence Therapeutics reported last 12-month revenue of $2M and negative EBITDA of ($85M).
In the same LTM period, Silence Therapeutics generated $841K in gross profit, ($85M) in EBITDA losses, and had net loss of ($83M).
Revenue (LTM)
Silence Therapeutics P&L
In the most recent fiscal year, Silence Therapeutics reported revenue of $559K and EBITDA of ($89M).
Silence Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | $559K | XXX | XXX | XXX |
| Gross Profit | $841K | XXX | $344K | XXX | XXX | XXX |
| Gross Margin | 54% | XXX | 62% | XXX | XXX | XXX |
| EBITDA | ($85M) | XXX | ($89M) | XXX | XXX | XXX |
| EBITDA Margin | (5527%) | XXX | (15957%) | XXX | XXX | XXX |
| EBIT Margin | (5494%) | XXX | (16056%) | XXX | XXX | XXX |
| Net Profit | ($83M) | XXX | ($89M) | XXX | XXX | XXX |
| Net Margin | (5353%) | XXX | (15852%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Silence Therapeutics Stock Performance
Silence Therapeutics has current market cap of $283M, and enterprise value of $198M.
Market Cap Evolution
Silence Therapeutics' stock price is $6.00.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $198M | $283M | 0.0% | XXX | XXX | XXX | $-1.88 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSilence Therapeutics Valuation Multiples
Silence Therapeutics trades at 128.3x EV/Revenue multiple, and (2.3x) EV/EBITDA.
EV / Revenue (LTM)
Silence Therapeutics Financial Valuation Multiples
As of April 10, 2026, Silence Therapeutics has market cap of $283M and EV of $198M.
Equity research analysts estimate Silence Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Silence Therapeutics has a P/E ratio of (3.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $283M | XXX | $283M | XXX | XXX | XXX |
| EV (current) | $198M | XXX | $198M | XXX | XXX | XXX |
| EV/Revenue | 128.3x | XXX | 355.0x | XXX | XXX | XXX |
| EV/EBITDA | (2.3x) | XXX | (2.2x) | XXX | XXX | XXX |
| EV/EBIT | (2.3x) | XXX | (2.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 236.0x | XXX | 576.9x | XXX | XXX | XXX |
| P/E | (3.4x) | XXX | (3.2x) | XXX | XXX | XXX |
| EV/FCF | (2.9x) | XXX | (3.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Silence Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Silence Therapeutics Margins & Growth Rates
Silence Therapeutics' revenue in the last 12 month grew by 183%.
Silence Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.8M for the same period.
Silence Therapeutics' rule of 40 is (1088%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Silence Therapeutics' rule of X is (120%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Silence Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 183% | XXX | 645% | XXX | XXX | XXX |
| EBITDA Margin | (5527%) | XXX | (15957%) | XXX | XXX | XXX |
| EBITDA Growth | (6%) | XXX | (19%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (1088%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (120%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3997% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4155% | XXX | 12125% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 16118% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Silence Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Editas Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Anavex Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Antibiotice | XXX | XXX | XXX | XXX | XXX | XXX |
| Foghorn Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Protara Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Silence Therapeutics M&A Activity
Silence Therapeutics acquired XXX companies to date.
Last acquisition by Silence Therapeutics was on XXXXXXXX, XXXXX. Silence Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Silence Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSilence Therapeutics Investment Activity
Silence Therapeutics invested in XXX companies to date.
Silence Therapeutics made its latest investment on XXXXXXXX, XXXXX. Silence Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Silence Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Silence Therapeutics
| When was Silence Therapeutics founded? | Silence Therapeutics was founded in 1994. |
| Where is Silence Therapeutics headquartered? | Silence Therapeutics is headquartered in United Kingdom. |
| How many employees does Silence Therapeutics have? | As of today, Silence Therapeutics has over 116 employees. |
| Who is the CEO of Silence Therapeutics? | Silence Therapeutics' CEO is Iain Gladstone Ross. |
| Is Silence Therapeutics publicly listed? | Yes, Silence Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of Silence Therapeutics? | Silence Therapeutics trades under SLN ticker. |
| When did Silence Therapeutics go public? | Silence Therapeutics went public in 2020. |
| Who are competitors of Silence Therapeutics? | Silence Therapeutics main competitors are Editas Medicine, Anavex Life Sciences, Antibiotice, Foghorn Therapeutics. |
| What is the current market cap of Silence Therapeutics? | Silence Therapeutics' current market cap is $283M. |
| What is the current revenue of Silence Therapeutics? | Silence Therapeutics' last 12 months revenue is $2M. |
| What is the current revenue growth of Silence Therapeutics? | Silence Therapeutics revenue growth (NTM/LTM) is 183%. |
| What is the current EV/Revenue multiple of Silence Therapeutics? | Current revenue multiple of Silence Therapeutics is 128.3x. |
| Is Silence Therapeutics profitable? | No, Silence Therapeutics is not profitable. |
| What is the current EBITDA of Silence Therapeutics? | Silence Therapeutics has negative EBITDA and is not profitable. |
| What is Silence Therapeutics' EBITDA margin? | Silence Therapeutics' last 12 months EBITDA margin is (5527%). |
| What is the current EV/EBITDA multiple of Silence Therapeutics? | Current EBITDA multiple of Silence Therapeutics is (2.3x). |
| What is the current FCF of Silence Therapeutics? | Silence Therapeutics' last 12 months FCF is ($69M). |
| What is Silence Therapeutics' FCF margin? | Silence Therapeutics' last 12 months FCF margin is (4469%). |
| What is the current EV/FCF multiple of Silence Therapeutics? | Current FCF multiple of Silence Therapeutics is (2.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.